PharmaShots | Incisive News in 3 Shots

Subscribe Now

Altimmune

Altimmune Reports 24 Week Interim Analysis Results of Pemvidutide in P-II Trial (MOMENTUM) and P-Ib Trial for Obesity and Type 2 Diabetes

Altimmune Reports 24 Week Interim Analysis Results of Pemvidutide in P-II Trial (MOMENTUM) and P-Ib Trial for Obesity and Type 2 D...

March 22, 2023

Altimmune Reports 24-Week (12-Week Extension) Trial Results of Pemvidutide for the Treatment of Non-Alcoholic Fatty Liver Disease

Altimmune Reports 24-Week (12-Week Extension) Trial Results of Pemvidutide for the Treatment of Non-Alcoholic Fatty Liver Disease

December 21, 2022

Top COVID-19 Deals (Part II): Biopharma Vaccine Development

Top COVID-19 Deals (Part II): Biopharma Vaccine Development

May 1, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us